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• Metelloporphyrlns and Tetrspyrroles as Acute 
Posltivo Inotropea in a Rat Model o! Myocsrditis 
R, KIm, J, Gocn, O, Knowles, R,S, Oanzigor, Columbia Untvent~ Now York, 
NY, USA 
B~c~groe, nd: Cyclic guanos(no monophata (cGMP) depresses myocardial 
contract[tRy, Matatloporphyrlns am naturally occurring Inhibitom of the activity 
of soluble guanylyl cyclaso (SGC), In the current study, we Investlgatsd the 
effect of an- and Zn.protopofphyrln tX (SnP ar~t ZnP) on s~,stsUc ardtec 
fonctlon In A mt modal of myocsrdltl~ tIP Isoprotorenot 3 mg~g x 2 dAya~, 
M~fhod~: A constant flow Lsngondo~ preparation with Intnot haAas was 
used to evaluate oardlno padormance, 
Re~u~: SnP (50 I~M) and ZnP (100) a(gn(flaanffy Increased maximum 
rata of IAft vantrlcular pressure (dP/dt) and (aft vAntrlculnr pressure (LVP) of 
myO~AKIttl0 ha~ls (P ~ 0,05, n ,~ 24), In0reased contrsctl(Ity pomlstad for u~ 
to two hours, the dumtlon of the experiments, Interestingly, SnP decreased 
aortic peffuslon pressure, suggsstlng that SaP reduced coren~W roslstanco, 
In control hearts, ZnP end SnP had no effect on contractility, In order to morn 
olonely llnk fha Inotmplc eftect of: ZnP and SnP in the my~rditle hearts to 
Inhlbitlon o! ~GC, we tlsod Protopoq~hyrin IX (PP}, a totrapyrrolo which does 
no1 inhibit SGC, and 1H.[t ,2,4]exAdla=olo (4.3,-~,lqulfloxalin.l.one (ODQ), 
s~(tto (nblb(tor of SGC, PP (100 i,M) did not affect conlracllllty while ODQ 
(100 nM) increased beth LVP and dP/dt (P - 0,05, a ,~ 4), 
Concloslon: ~GC aatMty contributes to aystoltc dysfunction In myocardi. 
tilt, It Is posslble that soluble guanylyl eyclaso is a tharape,ttc target end 
thAI sp~i~tq matat~apo~t~Vr(~s are useful In the treatment of myocardial 
dystu~t~on asetr,~lated w~tl'~ l ll~mreatlon, 
~ Effects of Aging on tht  Ntg l t l v t  Chmnotmpl¢= 
end Antl-~! Admnsrglc Actions of Adenosine In 
the Rat Head 
J, X~I, E~, Gag, EL Friedman, D,L, Snyder, J, He.ritz, A. Pellog. Allegheny 
UnNerslty Of the He~tth Sclencfls, Phlt~d~lphhl, PA, USA 
The effect Of aging on the anlt-adrenorglc actions el adenosine wee studied 
in v/re and tn vitro using adult (6 month old) and old [24 month old) Ftst~or 
344 rats, Adonoetno (0,01-0,1 .mol/'Kg), given a~ a rapid be~t~s ~nto the 
dght atdum, @xortod a nogallve chrenotroplc effect manifested as a dose 
dependent ransient prolongation of sinus cycle length (SCL), This ettoct 
was similar in both ago groups, Lu,, the peroent maximal prolongation ol 
SCL (%ASCL) ranged from 12 ± 2% to 63 t f4% in the adult and tram 
20 ~ 7% to 5"/ ~- 15% in the old rats, In the presence of isopmtsrenot (0,2 
~lg/kg/mln), the negative chronotropic action of adenosine was potentiated 
in the adull rats much morn than In the old mrs, i.e., %~,SCL ranged h~m 
60 ~: 28%, to 183 ~: 48% vs, 40 i 12% to 70 :l 13%, respectively (p - 
0.05), In addition, in the presence of isoproforenol, acute transient global 
myocardial hypoxla and rapid sinai pacing Induced atrial libnllatlon (AF) in 
all six old rats but in only one of the six adult rats (P - 0,05). Under those 
conditions, tho blOckade of A~ -adenosine receptors in the adult rats increase 
the frequency of induced AF to six out of the twelve, In vitro, adenosino's 
~ttenuation of either isoprotemnol- or forskolin-tnducod predaclien oi cAMP 
was significantly less in atrial membranes isolated from old vs. adult rats, 
Conclusion: The anti.adronergic action of adenosine, mediated by At -ado- 
nosing receptors, is attenuated in old vs. adult rat hoads, This could suggest 
redu~d oardioprotection by adenosine in elderly patients. 
~ Differential Effects of Procalnamlde and Verapamil 
on Ventrlcular Vulnerability in Isolated Rabbit 
Hearts 
R.J. Sung, Y,-W. Qian, S..F. Lie. Stanford Univ., Stanford, CA and VanderDdt 
Univ.. Nashville, TN, USA 
Background: Mechanisms of initiation and maintenance of ventricular fibrilla- 
tion (VF) are complex. We compared effects of Na*-channel and Ca" -chan- 
nel blockade on ventricular vulnerability and fibrillating wavefronts in isolated 
rabbit hearts. 
Methods: The ventricular vulnerable period (VVP) and the upper limit of 
vulnerability (ULV) were determined using shock energy of various strengths 
while scanning the electrocardiographic T-wave. Optical imaging using poten- 
tial-sensitive dye (di-4-ANEPPS) was utilized, without mechanical uncoupling 
agents, to assess the wavefront dynamics during and after delivery of shock 
($2) through internal eads in the pulmonaE, artery and left ventricu!~r apex. 
Procainamide (Pr, 0.1 raM) and verapamil (Ve, 1 I~M) were added to the 
perfusate in seven and four heads, respectively. 
Results: Pr significantly increased the midpoint c VP, but had no effects 
on ULV. It changed the direction of the principal reentrant pathways from 
~arallel to 45 ~ relative to fiber orientation. Further-more, Pr significantly pro- 
longed the dominant arrhythmic ycle length (ACL). In contrast, Ve slightly 
shifted VVP, but greatly shortened ACL. Fibrillating wavefronts disnJpted into 
small fragments with short condootion pathways after Vo treatment, 
mld.VVP (m~) ULV iV) ACL (ms) 
Control 143 t 12 212 • 39 101,9 ~ 11.3 
Pr 164 ~ 24' 213 ~ 42" 150a ¢ 196' 
Controt '123 ~ 5 t33 -~ :39 933 ~ 74 
Vo 133 ~: S' 143 ~ ~0" ?4~B -t lt,6 ° 
(' P • gas," p. NS) 
Conctu.'~lon: In isolated rabbit heads, Pr stabilizes VF possibly by readily. 
ing pmfomntisl conduction pathways, whereas Va may haw. Adv~ma f t ra  
an VF by shortening its ACL And fragmenting the wavotronta, 
Clinical Trials of Lipid Lowering Drugs 
Tuesday, March 3t, 1998, Noon-2:00 p,m. 
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Presentation Hour: Noon~t;O0 p,m, 
~ Insights Into •tat!n ll~atm~nt o! 
Hypedrlglyeer!demta 
b.A, Stoin, M,C, Lane, P,M. Laskaf~ewski. A~dical Research Lat)Or~toties, 
Highland Heighh~, KY, USA 
B~ckgmuna: The |ocus Of statlns has been on LDL-cbetestmot (LDL-C). A 
study in subjects with high tngly~efidde (To) with atorvastatin tater) reported 
reductions of 28 to 46% which wore dose misted, 
Purpose; To determine if: (a) all atatins were eff,x:tive in towenng TO; (b) 
the %. T 9 reduction was independent of baseline Tg as occurs for LDL-C; (c) 
the efficacy for Tg and LDL-C lowering were related. 
~thods: To standardize assessments we devised a ratio of % Tg reduc- 
tion ~- % LDL-C reduction (Tg/LDL.C ratio), The ratio for the Ator high T 9 
study was 1.6, 1.0 and 1.1 for 5, 20 and 80 mg respectS, very. 1"he mite tot 
a non-high Tg Ator study (To -:300 rag) was 0,B, 0.7 and 0,4 for the 5, 20 
and ~0 mg doses. We then carried out a "india.analysis* using 7 prevmusty 
reposed studies involving Sire, 5, 10, 20, 40, 80 and 160 n~l, tovastath~ |L'ov) 
at 20, 40 80 mg and pravastatin (Pro) at 10, 20, 40 rag. The protocols were 
el similar design; 4 wk placebo with randomized ouble-blind active thera.oy 
for 4-6 weeks. A total of 2689 subjects were included and for all protocols, 
entw Tg wore .~400 mg/dL. Baseline (eL) Tg were stmmtified at ~ 150 mcJtdl. 
150--250 mg/dL and >250 mgrdL 
Results: The data for all statins was consistent with Tg lowering highly 
related to BL TO. At Tg < 150 mg~dL minimal reduction Occurred and was not 
dose related. For BL Tg ~-250 mg/dL Tg reductions of 4S%, 44% and 35% 
were found for Sire 160 mg, Lov 80 mg and Pro 40 mg Irrespective of close 
or drug the Tg!LDL-C retie was as follows: BL Tg 150, Ratio 0.0 .. 0.3: eL 
T 9 150-250, Ratio 0.5 i 0.2; BI Tg ~250, Ration t.2 ~ 0.3. 
The Tg/LDL-C ratio was evaluated by linear models assessing SL TO, 
drug and dose. Only BL Tg was statistically significant (p -: 0.001). 
Conclusion: (a) Tg reduction by ststins is highly del~ ndent on BLTg. At 
higher BLTg, Tg reduction is close dependent. All statins will be effective 
in reducing Tg in high Tg subiects but statins with greater LDL-C reducing 
efficacy will also be more effective in reducing Tg. (b) The Tg/LDL-C ratio is 
fairly constant at any eL Tg level for all statins irrespective of dose and there 
(s a single mechanism involved in both Tg and LDL-C reduction. 
~ Delayed Progression of Atheroscterosis in 
Coronary Bypass Grafts Is Similar in Women 
Compared to Men Following Aggressive 
Cholesterol Lowering Despite More Frequent Risk 
Factors: Post CABG ~ial  
L. Campeau, G Knatterud, M Domanski, J.S. Forrester, N Geller, F Gobel. 
JA. Herd, B. Hoogwed, D.B. Hunninghake, C. White, Y. Rosenber9 
Montreal Heart Institute. Montreal, Quebec, Canada 
Background: The study is based on data from the Post Coronary Artery 
Bypass Grott (CABG) trial designed to determine the effect on atherosclerosis 
in saphenous vein grafts of 4 to 5 years of aggressive LDL-cholesterol 
towering to 93-97 mg/dl ~AL) and moderate towering to 132-136 rag/dr (ML). 
Methods: The prevalence of associated risk factors and the treatment 
effect (probability of progression) were compared in 1249 men (M) and 102 
women (W) of similar age (61,5 and 62.4 years). Eleven risk factors (RF) were 
studied: tamily histo~, diabetes metlitus, systolic and diastolic hypertension, 
smoking, no regaiar exercise, U3L cholesterol (C) >_160 mg/dl, HDL-C <35 
mg/dl, LDL-C/HDL-C >3, triglyceridas ~200 mg/dl and body mass index, 
Results: The mean number of RF in W was 5.0 ± 2.0 compared to 4.5 
1.7 in M (p = 0.002). Five RF were more frequent in W: 1emily history (80% 
JACC Fcbrua~ I~ AB~'IRACT$ - P.,,zer -~eIA 
vs 701, IP =, 0.02), systolic hyperten=ion (53% vs 42~, p = 003), dmbetes 
(171 w B%, p == 0,002), no m~ular exemise (79% v~ f101, p ,~ 0,001) and 
tngly~rlO~ (187 ~ 77 vs 158 ± 69 mg/~, p ,~ 0.001). The m~ttv~ nsk (RR) 
ol pmgmsston w~s simdm ~ both g(~lers 
Gendm ~ (%) P va~e nR (95% CI) 
Wom~ 14 8 ~.g 025 055 (0.L~I ~0) 
Men ~I.§ 40,1 ~O(X~t 0t~0 (0 47~0 73t 
Coect~:  TI~ hq~e_r pmvakmc~ of aseocmted risk t~¢-tom in won~t~ 
~1 nol dterum~h the ~ elte~ of aggm!siv~ cholesterol Iowenn9 m 
dataymg ~ vein grail a~:nmI:~s~li~to~is. 
~ 111~ 1 |vO~ O# ~rn¢~ Aq~rt~l A~k) t 'o f l l f l ,  in 
. . . . . . . . . . . .  ~ Wilh ~ Familial 
Hy l lXm~ok,~m}leml~ A!t~r 8tMin 11ttmll~ 
C,E. I~t~Os. J,D. ~ ,  JN. Skoumas, CI. A~i ,  S,G, I~lrnbrou, 
A.A, F ~ ,  C!, S te~,  PK Toutouzas L ~  at Ca~/~,  
~zrzlt~z~ut~ ~ ~ hyp~retemla  (hFH) Is assocq- 
ated wire an ~ risk of ~ .  The aim of mm sludy was Io 
datem'dne me evofulmn el daseendl~g thorac¢ aomz alhemmatous dmease 
(TAA) by ~ erhoca~gfa l~ (lqEE) m hFl-I patients after 
Io~-tem~ ~ mera~t ~ d~ and stam~r,. Sixteen patrols (7 
maim and 9 ~male~ mean age 47 ~ 12 yrs) wilh f~y  diagnoe, d hFH 
o:~mpased the study populatk0~t. An p~beofs unOefwerff a baseline TEE ex- 
aalatat~ ~r  wl~dl ~ ¢'t~[31 (:rz~1 alibi p r ' ~  (L~[)-40 n~ o.d) were 
initiated. ~ t  TEE was ped~m~ed after 2 y,zs of therapy. TAA was graded 
as follows: grede 0: no,real i r~a;  g~de |: inoreased intimal ecbede~s~ 
lh~ck~H~l o r lunlen t~j.d~t~; ~cld~. It: ~ illt~mal 
s~ w~h sm~ ~dl-defmed ameromatous i~que proWudmg .:3 mm intothe 
lun, m~ grade IlL ~ allleremas I~01n~ng <3 ram; grade IV: atheremas 
protmdm0 >3 n~ glade V: protmdm9 mollie of pedunculated ptaquas. 
~ :  As a result o~ treofment, LDL decreasea frem 294 _+ 56 n~O/dl to 
193 ~ 56 n~'dl (p < 0.025). Accoofin9 te beselme TEE, I pt was grada 0, 4 
pts were grade I, 6 pts were grade II, 3 pts were grade III and 2 were grade 
IV. Two years lat~ 7 pts did not change c~tegory, 3 pts showed prograsS~on 
of TAA (1 pt flora, gr-~de II to grade Ill and 2 pts from grade III to grade IV), 
v~le 6 pts showed re~-esston ot TAA (3 pts from made t to grade. 0 I~  
tram ~ It to grade o. 1 pt from It to ! and 1 pt from IV to III). Paben~ 
who improved We~B younger (39 ± 14 vs 52 ± 6 yrs, p < 0.025) rind less 
severe pretreatment TAA and had a greater LDL decrease (138 ± 56 vs 72.5 
54.5 mg,k;g, p < 0.025), compared with patients who remained stable or 
deteriorated. 
In ~on.  ior~ten'~ hypot@Ktemic d~et and treatment v~th pravestatm 
is ettectwe in produ~m~j TAA regressmn in young hFH pts with moderate 
atheromatesis. TEE is a v'alual~e method for the evaluation of these changes. 
' -~  Pravastatin Reduces Total in Patients With Mortel~y 
Coronary Heart Disease and A~,rage Cholesterol 
Levels: Relationship of Baseline Cholesterol and 
Treatment Effects in the LIPID 11rlal 
R.J. Simes. J. Baker. S. MacMahon. W. Hague. D. Colquhoun. M. West. 
M. Arulchelvam, J. Shaw. A. Tonkin. On behaff of the LIPID stu~ group: 
University of Syclrmy: National Hear Foundation. Australia 
Despite benefits of cholesterol owering treatment seen in eadier tnats, treat- 
ment effect on mortality in patients ,~th relat~ety hernial cholesterol levels 
has remained uncertain. The LIPID trial assessed long term effects of pravas- 
latin versus p~acebo ~n 9,104 patients with baseline total choleste rot of 4.0.-7.0 
mmol/L (155-271 m~cli) and a history of acute myocardial infarction (5,754; 
64%) or hospitalisation for unstable angina (3,260; 361). Major treatment 
outcomes included coronary mortality, total mortality, myocardial infarction, 
and stroke. The study was also designed to assess treatment effects by 
baseline lipids and changes in lipids on subsequent outcomes. The study 
included large numbers with relatively tow initia| cholesterol evels: 3,793 
(42%) with total cholasterol <5.5 mmoPL (213 mg]dl) and 2,678 (,30°/,4 v~th 
LDL cholesterol <3.5 mmol,l_ (136 mg/dl). 
Interim analysis has shown clear evidence of a reduction in total mortality 
with pravastatin (p < 0.003) and so the LIPID trial is clesing early with final 
analysis to be undertaken after patient visits are completed by September 30, 
1997. The relationship between baseline lipid levels and relative reductions 
in coronary events will be examined as well as the effect of lipid changes on 
subsequent coronary risk. Th=s large scale trial should enable the relationship 
of treatment effects with pravastatin and lipids to be estimated much more 
reliably. 
L=I~aW ~n~ SafmY of 0,S m9 oou~,  o! 
¢~t~In ,  s Novel HMG.CoA lqeducte~ Inhlbltor 
E. Stein ~ , J. lsaac~o~n ~ , R Stollz~. A Mazzu ~, IV.,C Li~, C, l.~me ~, 
A,H, Helk~P, 'Me~ and/ At't'teft~¢~rot,~ F ,~ch Cw~', Cmcmn, M~, 
OH, USA; ~ GFI I ~ ~ ~ , I ~ 4 ~  L~vatl~ ,  IN, ~;  ,~  
C~at~,  P~atm~em~ Ptvm~ vV~t ~1.  CT, USA 
C~f~v~n (CER) m a~ novel HMG.COA n~:luc~ mt~ltef I~  reduel~ 
chek~-leml level= ~t ~r~tow 00~es. Pmv~ ~tu~e~ up Io 0.¢ ~} pmdu¢~ 
a Io9 I~r  ¢lo~mspomm cu~ wflh LOL-¢bOk~t~ol (LDL.C) ~ of 
36%. 
~ -  To c~m,m~_ em ~ e~l ufmy at rERm 0,O m0~y 
~ -  In th~ 2B day mndomt~t~ doub~-bl~, pla¢~o (PLA),o~.. 
troUe¢l ~ II If~, 41 pltl~l~ ~ ~ ~ , , a  m 
t~ll~lL,~ on an AHA Ste~ I diet foe 4 'MN~J l~f  t~ ~ tO CER 
0.8 mO (n = 281 or PL~ (n = 13), ¢l~ly tn Ihe evef~l, LOL¢, t0tal rhOle~4m:d 
(1oral.C), HOL.C, ~ (TRIG) lind Lp(a) wefli~  m ~-...~,~ 
i ~ ,  All adv~me veofs were ~ .  
F~U/IS.' Chan~ =n I~  par~ (% from harm at each post,treat. 
ment vmtl) were as ~low~: 
Day a Day 1,5 Day 22 Day 29 
Parameter PLA CER PLA CER PLA CER Pl~ CER 
LDL-C F.0 -325 41 -37,?. 31 -434 1 2 -440 
To~aI.C 1 7 239 2.4 ~2e3 3.7 -301 ~ -30e 
HOL-C 20 20 - t2 1.0 31 2e -12 32 
TRIG -43 -14.5 t02 -18.9 96 -B7 159 -112 
CER s~gmficamty reduced tetal-C, LDL-C and l~ty~ftde ~ compare0 
m PLA Reduction~ m IoW-C and LDL-C were appmem after a days, and 
mammal by Day 22. All !paints completed the 2&-day treatment course. 
Ot~e patient, m the Iou~t~ week of treatme~ wilh CER, day.aped peh~c 
i n ~  disease. No patient e~l~ited ALT or AST elevatJ~ greater 
man2 ,, ULN. One patent, t~ l~ l  w~h CER a~e¢ l  an a~,pton-.a~ 
inc~rease in CK (8 ~ ULN) oft gle last day of Irealm~t. This value relumed 
to near nownel mx days la~. 
~ :  CER 0.8 mg produced an LDL-C raduction of 441 eon=s~mt 
with a continued tog linear dose ~ of 6% adl~nal LDL-C reduction 
for every CtDu~ng el dose. This rs~tt.¢tton m¢ompara~a with the t~he~ 
doses of the most effective stat~rts cu~ marketed 
[ -~- -~ Sitostanol ~ Added to Long-tern1 Shnvamatln 
Treatment of Coronary Patients With Low and High 
Basal Cholesterol Absorpt ion 
H. Gylling, T.A. Mietllnen. Oepar/ment o: Medcm~ Unme~rty of" t-telslnkl. 
Fin/and 
Ba~grounu. A simvastatm-treated subgroup, not reduong recurrence oi ma. 
lor coronary e~s ,  was ,~Bparaled horn 45 by high ba~d seru~ cholestanol 
and plant sterol and low precursor sterol ratios suggesting that they had 
hfgh absotpl~m and low synff~emis of cholesterol. We assumed tt~t the 
non-respon~rs might be more ~ to ~ostand est~ mmgmme 
(SEM)-induced c~asterel ma~L-~on.  
Method: From a coronary group treated over a year with stmvastatm, 
higllest (H;n = 15) and lowest (L'n = 15) absorbers were s~Heofed by glair 
basal chofestano~cholesterel ratio and treated for 3 monff~ with SEM. 
Resu/ts.- Basal total and LDL choleslerel values and 1heir simvaMalkl-ln- 
duced redudions were similar in H and L while the re~:,~h/e cholestrnol 
and plant sterol ratios were 1.6-1,9 times higher in H than L Addition of SEM 
further decreased total (-7.6 ± 2~/=) and LDL (-11.7 + 3.51) cholesterol 
in H (P < 0.01). while in L the reductions were nonsignificant. Reductions 
of cholestanol and plant sterol ratios and the increases of precursor sterol 
ratios were similar in the two groups. 
Conclusion: Coronary patients on simvastattn with high baseline rhotas- 
tarot absorption are benefitled tram sttostanol-induced cholesterol malab- 
sorption as compared to those w~th.low absorption and high synthesis. Non- 
responsiveness to stalin may contribute to lacking recurrence of coronary 
events. 
~ Basal Non-cholesterol Sterol$ Reveal a Subgroup 
of 4S Not Benefitted by Slmvesttltin-lnduced 
Decrease of Recurrent Coronary Events 
T.A. Miettinen, H, Gylling. Department of Medicine, University of He/sinki, 
Finland 
Ba,.,~ground: InScandinavian Sir'm, astatin Survival Study (4S) stmvestatin-in- 
duced ,eduction of coronary events (CE) was not predicted by baseline Iipids. 
The increasing quartiles at the t~as~l cholesterol (C) precursor steml (IS)/C 
